Maps show U.S. air quality and Canada wildfire smoke forecast
Smoke spreading from wildfires in Canada was affecting air quality in multiple states on Tuesday.
Parts of Minnesota, Iowa and Wisconsin were most at risk for unhealthy air, according to a federal measurement system called the Air Quality Index.
The index has six ratings: good, moderate, unhealthy for sensitives groups, unhealthy, very unhealthy and hazardous. Sensitive groups include those who have a heart or lung disease, as well as older adults, children and pregnant women.
The map below shows the current air quality across the U.S.
Other states, including Illinois, Michigan, Ohio, Pennsylvania and West Virginia, may see smoke from the fires, although the thickness will vary.
In the Philadelphia region, for example, while smoke is expected to be visible, no major impacts on air quality are expected, CBS Philadelphia reported.
Here's a look at where the smoke is expected to move on Tuesday and Wednesday.
The Canadian wildfire smoke forecast for Tuesday, June 3, 2025, at 8 p.m. ET.
CBS News
The Canadian wildfire smoke forecast for Wednesday, June 4, 2025, at 8 a.m. ET.
CBS News
The Canadian wildfire smoke forecast for Wednesday, June 4, 2025, at 8 p.m. ET.
CBS News
Around 200 active fires are burning in Canada, according to the Canadian Interagency Forest Fire Centre. More than 25,000 residents across three provinces had been evacuated due to the blazes as of Sunday, The Associated Press reported.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
an hour ago
- New York Times
Selfishness Is Not a Virtue
When Christianity goes wrong, it goes wrong in a familiar way. Last Friday, at a town hall meeting in Butler County, Iowa, Senator Joni Ernst delivered a grim message to her constituents. In the midst of an exchange over Medicaid cuts in President Trump's 'big, beautiful bill,' someone in the crowd shouted at Ernst, 'People are going to die!' Ernst's immediate response was bizarre. 'Well, we all are going to die,' she said. True enough, but that's irrelevant to the question at hand. Yes, we're all going to die, but it matters a great deal when, how and why. There's a tremendous difference between dying after living a long and full life that's enabled at least in part by access to decent health care, and dying a premature and perhaps needlessly painful death because you can't afford the care you need. All of this should be too obvious to explain, and it would cost Ernst — who occupies a relatively safe seat in an increasingly red state — virtually nothing to apologize and move on. In fact, just after her flippant comment, she did emphasize that she wanted to protect vulnerable people. The full answer was more complicated than the headline-generating quip. By the standards of 2025, Ernst's comment would have been little more than a micro-scandal, gone by the end of the day. And if we lived even in the relatively recent past, demonstrating humility could have worked to her benefit. It can be inspiring to watch a person genuinely apologize. But we're in a new normal now. That means no apologies. That means doubling down. And that can also mean tying your cruelty to the Christian cross. And so, the next day Ernst posted an apology video — filmed, incredibly enough, in what appears to be a cemetery. It began well. 'I would like to take this opportunity,' she said, 'to sincerely apologize for a statement I made yesterday at my town hall.' But her statement devolved from there. Want all of The Times? Subscribe.
Medscape
an hour ago
- Medscape
Biomarker sNfL Falls Short for MS Diagnosis, Experts Say
PHOENIX — Despite its growing role in monitoring treatment response and disease activity in multiple sclerosis (MS), serum neurofilament light chain (sNfL) lacks the specificity needed for diagnosis and will not be included in upcoming revisions to the McDonald criteria, experts say. In addition to monitoring treatment response, sNfL has the potential to eventually play a part in predicting disease course, 'but diagnosis? Not so much,' said Tanuja Chitnis, MD, senior neurologist, Brigham M ultiple S clerosis Center, Harvard Medical School, Boston, at the Consortium of Multiple Sclerosis Centers (CMSC) 2025 Annual Meeting. This not only applies to sNfL but other fluid biomarkers, including glial fibrillary acidic protein (GFAP), which has enormous promise for tracking and understanding the course of MS but also needs context and has important limitations. 'We do not yet know for sure what the updated McDonald criteria will recommend specifically, but sNfL is not very helpful for diagnosis,' said Mark Freedman, MD, director of the Multiple Sclerosis Research Unit at the University of Ottawa, Ottawa, Ontario, Canada. He, like Chitnis, does not see sNfL as a diagnostic tool either as an isolated value or in the context of other currently available signs of disease. Most, if not all, patients with a diagnosis of MS who are eventually confirmed typically have elevated levels of sNfL, but Freedman, who led the symposium on fluid biomarkers said this information is not helpful. And sNfL, he noted climbs with neurodegeneration, but this is not unique to MS. Many other diseases associated with neuronal damage, including amyotrophic lateral sclerosis, are linked to much higher sNfL levels at diagnosis, underscoring its poor specificity, said Freedman, who has led consensus papers on its use. The most recent was published in 2024 on behalf of the CMSC. An Indicator of Response Chitnis said sNfL may eventually play a role in MS diagnosis when combined with other variables, including fluid biomarkers, but for now, its primary value lies in disease management, where it serves as a sensitive tool for monitoring treatment response. A sensitive indicator of disease activity sNfL provides information beyond MRI, said Chitnis, who tracks levels every 3-6 months after initiating or switching therapy. A lack of decline may signal inadequate disease control. Freedman echoed this view, noting that if levels don't drop within a few months of starting treatment, he begins to question its effectiveness — even before other signs of treatment failure appear. 'If I do not see sNfL fall within a few months of starting therapy, I start questioning the therapy,' he said. The clinical value of sNfL was highlighted in a 2023 CSMC consensus paper, which endorsed its use for tracking recovery after relapse, guiding therapy decisions, and clarifying discrepancies between MRI and clinical findings. Since then, evidence supporting its use has only strengthened, Freedman said. 'The tests are now accessible everywhere,' he said. He also noted that there is growing confidence that sNfL is a substitute for MRI in many specific scenarios, such as when access to MRI is limited by cost or distance to an imaging device. Multiple sNfL assays are available, but they are not interchangeable. They vary in sensitivity, turnaround time, methodology, and cutoff values — so any changes in sNfL levels must be tracked using the same assay throughout. 'We have to be careful about using apps to interpret the results,' Chitnis cautioned, noting that such tools are now commercially available. She added that interpretation also depends on the reference population and can be influenced by factors like body mass index, renal function, and age. 'A Novel Window Into the Brain' The value of sNfL in monitoring treatment response — and in tasks such as assessing disease activity in patients with MS who have discontinued DMT — may be just the beginning for this biomarker, which is under active investigation for a range of additional uses, said Chitnis. She noted that the clinical utility of fluid biomarkers like sNfL is likely to expand significantly as researchers learn how to interpret them in combination. In several studies, pairing sNfL with GFAP has offered new insights into progressive MS, particularly when the two markers trend in opposite directions. Despite an imperfect correlation, patients with high GFAP but low sNfL, relative to the other way around, 'probably represent our nonactive secondary progressive MS disease cohort,' Chitnis said. 'This is getting at our understanding of who might be more progressive in regard to the loss of the glial structure in the brain,' she added. Meanwhile, other potential biomarkers associated with increased clinical and radiological MS activity are showing promise. In a recent study led by Chitnis, a panel of 20 such proteins correlated more precisely with gadolinium lesion activity, clinical relapse, and annualized relapse rate than sNfL alone. Ultimately, fluid biomarkers like sNfL are providing 'a novel window into the brain' relevant not just to monitoring disease but potentially revealing the sequence of underlying pathophysiology of MS, said Chitnis. These appear to differentiate relatively benign disease from events leading to the irreversible damage of late stages progression.
Yahoo
2 hours ago
- Yahoo
Twins Announce Unfortunate Carlos Correa News Before Athletics Game
Twins Announce Unfortunate Carlos Correa News Before Athletics Game originally appeared on Athlon Sports. The Minnesota Twins enter Wednesday night's game against the Athletics with a 33-27 record that ranks second in the American League Central division. Six games back of the Detroit Tigers, Minnesota owns a half-game lead over the Cleveland Guardians who won the division last season. Advertisement One of the reasons for Minnesota's success this season has been the health of its best players. In previous years, all three of Carlos Correa, Byron Buxton and Royce Lewis have missed significant time. While Lewis has spent time on the injured list this season, both Correa and Buxton have remained healthier than in previous years. Minnesota Twins shortstop Carlos Correa (4)Brett Davis-Imagn Images Appearing in 52 of Minnesota's 60 games this season, Correa owns a .665 OPS that is well down from his .905 mark when he was an All-Star last season. That said, the three-time All-Star is still a needed presence in the Twins' lineup, as his defense at shortstop has been among MLB's best since his debut in 2015. Initially slotted to play short and bat fourth in Wednesday's contest, Correa was scratched with back tightness. The Twins announced this unfortunate news in a post on X. Advertisement "Updated lineup: Brooks Lee will play SS tonight," the team wrote. "Carlos Correa has been scratched with back tightness." While Lee is an exciting switch-hitting infielder, he has yet to find his footing at the Major League level. In 358 plate appearances since debuting last season, the 24-year-old has just a 70 OPS+ that rate well-below league average. For now, Minnesota will hope the Correa issue is not too serious, but it will hold him out on Wednesday night. Related: Paul Skenes' Reaction After Leaving Astros Game Turns Heads Related: Tigers Announce Unfortunate Kerry Carpenter News Before White Sox Game This story was originally reported by Athlon Sports on Jun 5, 2025, where it first appeared.
